☆ 4.5 Letter

A novel machine-learning-derived genetic score correlates with measurable residual disease and is highly predictive of outcome in acute myeloid leukemia with mutated NPM1

BLOOD CANCER JOURNAL (2019)

Journal

BLOOD CANCER JOURNAL

Volume 9, Issue -, Pages -

Publisher

NATURE PUBLISHING GROUP

DOI: 10.1038/s41408-019-0244-2

Keywords

-

Categories

Oncology Hematology

Funding

Wellcome Trust/DBT India Alliance Fellowship [IA/CPHI/14/1/501485]

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Hematology

Measurable residual disease detected by flow cytometry independently predicts prognoses of NPM1-mutated acute myeloid leukemia

Yun-Wei Zhang, Long Su, Ye-Hui Tan, Hai Lin, Xiao-Liang Liu, Qiu-Ju Liu, Jing-Nan Sun, Ming Zhang, Ya-Zhe Du, Fei Song, Wei Han, Su-Jun Gao

Summary: AML with NPM1 mutation is a distinct genetic entity with favorable outcomes. However, this study reveals that it is still a highly heterogeneous disorder. High NPM1 variant allele frequency (VAF) and certain co-mutated genes are associated with poorer outcomes. Additionally, measurable residual disease (MRD) after chemotherapy is an independent predictor. These findings are important for re-stratifying the prognoses of AML patients with NPM1 mutations.

ANNALS OF HEMATOLOGY (2023)

Add to Collection

Article Oncology

Measurable residual disease, FLT3-ITD mutation, and disease status have independent prognostic influence on outcome of allogeneic stem cell transplantation in NPM1-mutated acute myeloid leukemia

Rama Al Hamed, Myriam Labopin, Etienne Daguindau, Riitta Niittyvuopio, Anne Huynh, Gerard Socie, Micha Srour, Jean Henri Bourhis, Nicolaus Kroeger, Eleni Tholouli, Goda Choi, Xavier Poire, Hans Martin, Marie-Therese Rubio, Pavel Jindra, Didier Blaise, Dietrich Beelen, Helene Labussiere-Wallet, Arnon Nagler, Ali Bazarbachi, Mohamad Mohty

Summary: The presence of FLT3-ITD mutation, MRD positivity, and disease status significantly influence the posttransplant outcomes in patients with NPM1-mutated AML, highlighting the importance of identifying high-risk patients for potential posttransplant interventions to prevent relapse.

CANCER MEDICINE (2022)

Add to Collection

Review Hematology

NPM1-mutated acute myeloid leukemia: New pathogenetic and therapeutic insights and open questions

Brunangelo Falini

Summary: The importance and relevance of NPM1 mutations in AML, including their involvement in chromatin-level regulation and gene expression, as well as their implications for classification and potential targeted therapies.

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Add to Collection

Review Biochemistry & Molecular Biology

Neoantigen-Specific T-Cell Immune Responses: The Paradigm of NPM1-Mutated Acute Myeloid Leukemia

Fabio Forghieri, Giovanni Riva, Ivana Lagreca, Patrizia Barozzi, Francesca Bettelli, Ambra Paolini, Vincenzo Nasillo, Beatrice Lusenti, Valeria Pioli, Davide Giusti, Andrea Gilioli, Corrado Colasante, Laura Galassi, Hillary Catellani, Francesca Donatelli, Annalisa Talami, Rossana Maffei, Silvia Martinelli, Leonardo Potenza, Roberto Marasca, Enrico Tagliafico, Rossella Manfredini, Tommaso Trenti, Patrizia Comoli, Mario Luppi

Summary: The C-terminal aminoacidic sequence from NPM1-mutated protein may serve as a leukemia-specific antigen, and different in silico instruments have identified the most immunogenic epitopes. Spontaneous development of endogenous NPM1-mutated-specific cytotoxic T cells has been observed in patients.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Article Oncology

Cytogenetic abnormalities in NPM1-mutated acute myeloid leukemia

Weijia Fu, Aijie Huang, Lili Xu, Yanni Peng, Lei Gao, Li Chen, Jie Chen, Gusheng Tang, Jianmin Yang, Xiong Ni

Summary: Cytogenetic abnormalities are significantly associated with a worse prognosis in NPM1(mut) acute myeloid leukemia (AML) patients, and patients who undergo alloHSCT have longer survival.

LEUKEMIA & LYMPHOMA (2022)

Add to Collection

Review Oncology

Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia

Marisa J. L. Aitken, Farhad Ravandi, Keyur P. Patel, Nicholas J. Short

Summary: Quantification of measurable residual disease (MRD) provides critical prognostic information in acute myeloid leukemia (AML), with different detection platforms having varying sensitivity and applicability. MRD negativity is associated with reduced risk of relapse in AML, but the therapeutic implications remain unclear and require further investigation.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

Add to Collection

Article Oncology

Measurable Residual Disease in High-Risk Acute Myeloid Leukemia

Thomas Cluzeau, Roberto M. Lemoli, James McCloskey, Todd Cooper

Summary: Assessment of measurable residual disease (MRD) is important in predicting outcomes and managing high-risk acute myeloid leukemia (AML). However, there is currently no consensus on the best method for determining MRD negativity, making comparisons across studies difficult.

CANCERS (2022)

Add to Collection

Article Hematology

Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1

Guadalupe Onate, Alex Bataller, Ana Garrido, Montserrat Hoyos, Montserrat Arnan, Susana Vives, Rosa Coll, Mar Tormo, Antonia Sampol, Lourdes Escoda, Olga Salamero, Antoni Garcia, Joan Bargay, Alba Aljarilla, Josep F. Nomdedeu, Jordi Esteve, Jorge Sierra, Marta Pratcorona

Summary: This study analyzed the impact of DNMT3A(mut) in FLT3-ITD subsets and found that DNMT3A(mut) did not modify the overall prognosis exerted by FLT3-ITD in AML-NPM1, despite delayed MRD clearance, possibly because of MRD-driven preemptive intervention.

BLOOD ADVANCES (2022)

Add to Collection

Editorial Material Oncology

Clinical Impact of Measurable Residual Disease in Acute Myeloid Leukemia

Tali Azenkot, Brian A. Jonas

Summary: Measurable residual disease (MRD) has become a primary marker of risk severity and prognosis in acute myeloid leukemia (AML). However, there is ongoing debate about the monitoring and treatment based on MRD. The identified literature has described the prognostic value of pre-transplant MRD and suggested optimal timing and techniques to quantify MRD. Several studies have addressed the implications of MRD on treatment selection and hematopoietic stem cell transplant, but more prospective, randomized studies are needed to guide the application of MRD in AML treatment, particularly in transplantation.

CANCERS (2022)

Add to Collection

Article Multidisciplinary Sciences

Biological and therapeutic implications of a unique subtype of NPM1 mutated AML

Arvind Singh Mer, Emily M. Heath, Seyed Ali Madani Tonekaboni, Nergiz Dogan-Artun, Sisira Kadambat Nair, Alex Murison, Laura Garcia-Prat, Liran Shlush, Rose Hurren, Veronique Voisin, Gary D. Bader, Corey Nislow, Mattias Rantalainen, Soren Lehmann, Mark Gower, Cynthia J. Guidos, Mathieu Lupien, John E. Dick, Mark D. Minden, Aaron D. Schimmer, Benjamin Haibe-Kains

Summary: The molecular heterogeneity of AML poses challenges for prognosis and therapy. NPM1 mutated AML is heterogeneous, with two subtypes exhibiting distinct molecular characteristics, differentiation state, patient survival, and drug response.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Hematology

Comparison of RNA- and DNA-based methods for measurable residual disease analysis in NPM1-mutated acute myeloid leukemia

Louise Pettersson, Sofie Johansson Alm, Alvar Almstedt, Yilun Chen, Gustav Orrsjo, Giti Shah-Barkhordar, Li Zhou, Heike Kotarsky, Karina Vidovic, Julia Asp, Vladimir Lazarevic, Lao H. Saal, Linda Fogelstrand, Mats Ehinger

Summary: In this study, DNA-based methods were compared with RT-qPCR in assessing MRD in NPM1-mutated AML patients. The DNA-based methods showed less sensitivity but provided high positive and negative predictive values, crucial for diagnosing residual leukemia. Transitioning to DNA-based MRD methods may miss some patients with residual leukemic RNA, but can also detect MRD samples with measurable leukemic DNA lacking RNA.

INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

Memory-like NK cells armed with a neoepitope-specific CAR exhibit potent activity against NPM1 mutated acute myeloid leukemia

Han Dong, James Dongjoo Ham, Guangan Hu, Guozhu Xie, Juliana Vergara, Yong Liang, Alaa Ali, Mubin Tarannum, Hannah Donner, Joanna Baginska, Yasmin Abdulhamid, Khanhlinh Dinh, Robert J. Soiffer, Jerome Ritz, Laurie H. Glimcher, Jianzhu Chen, Rizwan Romee

Summary: Recent studies have shown that natural killer (NK) cells exhibit innate memory and enhanced antitumor activity upon activation with IL-12 and IL-18, providing a potential therapeutic approach for acute myeloid leukemia (AML). This study demonstrates that arming NK cells with a specific chimeric antigen receptor (CAR) significantly improves their antitumor responses to AML while avoiding off-target toxicity. These findings suggest the potential of using CAR-expressing NK cells for the treatment of AML.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2022)

Add to Collection

Review Oncology

Acute Myeloid Leukemia Stem Cells in Minimal/Measurable Residual Disease Detection

Kritika Srinivasan Rajsri, Nainita Roy, Sohini Chakraborty

Summary: Acute myeloid leukemia (AML) is a blood cancer characterized by immature blood cells called leukemic blasts. Leukemia stem cells (LSCs) are resistant to chemotherapy and can cause disease relapse. Understanding the molecular basis of LSCs is important in identifying and targeting these cells for more effective treatment.

CANCERS (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Effective NPM1 plasmid standards selection for minimal/measurable residual disease monitoring in acute myeloid leukemia

Adam Folta, Marketa Sasinkova, Anna Durinikova, Marie Drncova, Barbora Weinbergerova, Jiri Mayer, Ivana Jeziskova

Summary: Researchers have developed a PCR method to simplify the preparation of NPM1 plasmid standards and accurately distinguish different NPM1 mutation plasmids. This method is faster, more convenient, and more cost-effective than traditional approaches.

MOLECULAR BIOLOGY REPORTS (2022)

Add to Collection

Article Multidisciplinary Sciences

Memory-like NK cells armed with a neoepitope-specific CAR exhibit potent activity against NPM1 mutated acute myeloid leukemia

Han Dong, James Dongjoo Ham, Guangan Hu, Guozhu Xie, Juliana Vergara, Yong Liang, Alaa Ali, Mubin Tarannum, Hannah Donner, Joanna Baginska, Yasmin Abdulhamid, Khanhlinh Dinh, Robert J. Soiffer, Jerome Ritz, Laurie H. Glimcher, Jianzhu Chen, Rizwan Romee

Summary: Acute myeloid leukemia (AML) is difficult to treat due to a lack of tumor-specific targets for immune-based therapies. Recent studies have shown that natural killer (NK) cells exhibit innate memory and enhanced antitumor activity when activated with IL-12 and IL-18. This study demonstrates that arming CIML NK cells with a neoepitope-specific CAR significantly improves their antitumor responses to NPM1-mutated AML and avoids off-target toxicity.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2022)

Add to Collection

Letter Hematology

Cytogenetic profile and outcome of a pediatric acute promyelocytic leukemia patient presenting with isolated isochromosome 17q in absence of RARA rearrangement

Hemani Jain, Dhanlaxmi Shetty, Gaurav Narula, Nirmalya Roy Moulik, Prashant Tembhare, Nikhil Patkar, P. G. Subramanian, Sripad Banavali

BLOOD CELLS MOLECULES AND DISEASES (2021)

Add to Collection

Article Medical Laboratory Technology

Mast cell differentiation of leukemic blasts in diverse myeloid neoplasms: A potential pre-myelomastocytic leukemia condition

Devasis Panda, Gaurav Chatterjee, Twinkle Khanka, Sitaram Ghogale, Yajamanam Badrinath, Nilesh Deshpande, Rohan Sardana, Anumeha Chaturvedi, Sweta Rajpal, Dhanalaxmi Shetty, Nikhil Patkar, Sumeet Gujral, Papagudi G. Subramanian, Prashant R. Tembhare

Summary: This study reported a rare finding of MC differentiation of leukemic blasts in diverse myeloid neoplasms and proposed it as a potential pre-myelomastocytic leukemia condition. The distinct immunophenotypic signature of immature-MCs using commonly used markers was described, highlighting the utility of FCI for the diagnosis of this entity.

CYTOMETRY PART B-CLINICAL CYTOMETRY (2021)

Add to Collection

Article Oncology

Genetic ablation of pregnancy zone protein promotes breast cancer progression by activating TGF-β/SMAD signaling

Rohit Kumar, Ekaterina Kuligina, Anna Sokolenko, Quadir Siddiqui, Nilesh Gardi, Sudeep Gupta, Ashok K. Varma, Syed K. Hasan

Summary: The study revealed that genetic ablation of PZP results in tumor progression, and low expression of PZP is associated with poor survival of breast cancer patients.

BREAST CANCER RESEARCH AND TREATMENT (2021)

Add to Collection

Article Oncology

Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML)

Nikhil Patkar, Chinmayee Kakirde, Anam Fatima Shaikh, Rakhi Salve, Prasanna Bhanshe, Gaurav Chatterjee, Sweta Rajpal, Swapnali Joshi, Shruti Chaudhary, Rohan Kodgule, Sitaram Ghoghale, Nilesh Deshpande, Dhanalaxmi Shetty, Syed Hasan Khizer, Hasmukh Jain, Bhausaheb Bagal, Hari Menon, Navin Khattry, Manju Sengar, Prashant Tembhare, Papagudi Subramanian, Sumeet Gujral

Summary: NGS-MRD is an effective tool for predicting relapse risk and prognosis in AML patients, particularly in those with intermediate cytogenetic risk and favorable cytogenetic risk. The kinetics of NGS-MRD clearance is crucial for patient survival. Combining NGS-MRD with FCM-MRD provides comprehensive information for better clinical management.

LEUKEMIA (2021)

Add to Collection

Article Hematology

Mimics and artefacts of measurable residual disease in a highly sensitive multicolour flow cytometry assay for B-lymphoblastic leukaemia/lymphoma: critical consideration for analysis of measurable residual disease

Gaurav Chatterjee, Harshini Sriram, Sitaram Ghogale, Nilesh Deshpande, Twinkle Khanka, Karishma Girase, Shefali Verma, Gauri Arolkar, Niharika Dasgupta, Gaurav Narula, Dhanalaxmi Shetty, Chetan Dhamne, Nirmalya R. Moulik, Sweta Rajpal, Nikhil Patkar, Shripad Banavali, Sumeet Gujral, Papagudi G. Subramanian, Prashant R. Tembhare

Summary: The study identifies six consistently present low-level populations in 441 BMRD samples from 301 children, which immunophenotypically mimic abnormal B-ALL blasts. Understanding the presence and immunophenotype of these mimics is crucial for accurate interpretation in high-sensitivity MFC-BMRD analysis.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

Add to Collection

Article Hematology

Mutational landscape of Juvenile Myelomonocytic Leukemia (JMML)-A real-world context

Shrinidhi Nathany, Gaurav Chatterjee, Shruti Ghai, Nirmalya Roy Moulik, Dhanalaxmi Shetty, P. G. Subramanian, Prashant Tembhare, Sumeet Gujral, Chetan Dhamne, Sripad Banavali, Gaurav Narula, Nikhil Patkar

Summary: Juvenile myelomonocytic leukemia (JMML) is a rare childhood neoplasm categorized under myelodysplastic/myeloproliferative neoplasms. A low-cost targeted myeloid panel was developed to comprehensively evaluate the genomic profile of JMML, revealing that almost 90% of patients have at least one mutation, with the most common mutations found in RAS/MAPK-pathway genes. Monosomy 7 was detected in 32% of patients, with implications for overall survival.

INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2021)

Add to Collection

Article Medical Laboratory Technology

Improved protocol for plasma microRNA extraction and comparison of commercial kits

Harshini Sriram, Twinkle Khanka, Shweta Kedia, Priyanka Tyagi, Sitaram Ghogale, Nilesh Deshpande, Gaurav Chatterjee, Sweta Rajpal, Nikhil Patkar, Papagudi G. Subramanian, Sumeet Gujral, Syed Hasan, Prashant R. Tembhare

Summary: MicroRNAs, small non-coding RNA molecules, are increasingly used as biomarkers in diseases with challenges due to their low abundance in serum/plasma. This study compared four commercial kits and found that the miRNeasy Serum/Plasma kit performed the best in terms of quality and quantity of microRNA isolated, with a modified protocol further enhancing its performance.

BIOCHEMIA MEDICA (2021)

Add to Collection

Article Medicine, General & Internal

Genomic Analysis of AZD1222 (ChAdOx1) Vaccine Breakthrough Infections in the City of Mumbai

Arusha Shetty, Gaurav Chatterjee, Sweta Rajpal, Tuhina Srivastava, Nilesh Gardi, Sumeet Mirgh, Anant Gokarn, Sachin Punatar, Nitin Shetty, Amit Joshi, Sudhir Nair, Vedang Murthy, Navin Khattry, Prashant Tembhare, Rajesh Dikshit, Pankaj Chaturvedi, Ashwini More, Sujeet Kamtalwar, Preeti Chavan, Vivek Bhat, Amar Patil, Sachin Dhumal, Prashant Bhat, Papagudi Subramanian, Sumeet Gujral, Rajendra Badwe, Nikhil Patkar, Sudeep Gupta

Summary: This study analyzed the genetic features of SARS-CoV-2 mutations, prevalent phylogenetic lineages, and the disease severity among COVID-19-vaccinated individuals in a tertiary cancer hospital during the second wave of the pandemic in Mumbai, India. The study found that the kappa B.1.1671.1 and delta B.1.617.2 variants were prevalent among both vaccinated and unvaccinated individuals. The second dose of the vaccine was associated with a lower severity of COVID-19.

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2022)

Add to Collection

Editorial Material Oncology

Editorial: Metabolic Rewiring in Leukemias

Nelida I. Noguera, Syed K. Hasan, Emanuele Ammatuna, Adriano Venditti

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Medical Laboratory Technology

Detecting hypodiploidy with endoreduplication and masked hypodiploidy in B-cell acute lymphoblastic leukemia using multicolor flow cytometry

Anumeha Chaturvedi, Dhanalaxmi Shetty, Sitaram Gundu Ghogale, Nilesh Deshpande, Yajamanam Badrinath, Gaurav Chatterjee, Karishma Girase, Harshini Sriram, Twinkle Khanka, Chetna Mishra, Niharika Dasgupta, Sejal Anil Gujarathi, Sweta Rajpal, Nikhil Patkar, Prathibha Amare-Kadam, Sumeet Gujral, Papagudi Ganesan Subramanian, Prashant Ramesh Tembhare

Summary: Multicolor flow cytometry-based DNA-ploidy (MFC-ploidy) analysis shows a characteristic pattern in samples with endoreduplication and can distinguish between masked hypodiploidy and true hyperdiploidy in B-cell acute lymphoblastic leukemia (B-ALL). An integrated approach involving cytogenetic and MFC-ploidy detection is highly valuable for risk stratification of B-ALL in routine clinical practice.

CYTOMETRY PART B-CLINICAL CYTOMETRY (2022)

Add to Collection

Editorial Material Hematology

United we stand, divided we fall. Multicentre standardization of measurable residual disease assessment in acute leukaemia is the way forward

Gaurav Chatterjee, Nikhil Patkar

Summary: This article presents a routine method for assessing measurable residual disease in precursor B-cell acute lymphoblastic leukemia, and proposes a multicenter standardization using EuroFlow protocols.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Add to Collection

Article Medical Laboratory Technology

Expression levels and patterns of B-cell maturation antigen in newly diagnosed and relapsed multiple myeloma patients from Indian subcontinent

Harshini Sriram, Florence Kunjachan, Twinkle Khanka, Sangamitra Gawai, Sitaram Ghogale, Nilesh Deshpande, Karishma Girase, Jagruti Patil, Gaurav Chatterjee, Sweta Rajpal, Nikhil Patkar, Bhausaheb Bagal, Hasmukh Jain, Manju Sengar, Syed Khizer Hasan, Navin Khattry, Papagudi G. Subramanian, Sumeet Gujral, Prashant R. Tembhare

Summary: This study investigated the expression pattern of BCMA in abnormal plasma cells of multiple myeloma (MM) patients from India. The findings showed that BCMA is highly expressed in a majority of MM patients, both at diagnosis and relapse. This suggests that BCMA could be an important target for therapy in Indian MM patients.

CYTOMETRY PART B-CLINICAL CYTOMETRY (2022)

Add to Collection

Letter Hematology

Acute basophilic leukemia in a patient with down syndrome: A case report and review of literature

Anu Singh, Dhanlaxmi Shetty, Jagruti Patil, Manisha More, Gaurav Chatterjee, Sweta Rajpal, Nikhil V. Patkar, Papagudi G. Subramanian, Sumeet Gujral, Prashant R. Tembhare

INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2023)

Add to Collection

Article Hematology

Treatment and follow-up of children with chronic myeloid leukaemia in chronic phase (CML-CP) in the tyrosine kinase inhibitor (TKI) era-Two decades of experience from the Tata Memorial Hospital paediatric CML (pCML) cohort

Nirmalya Roy Moulik, Swaminathan Keerthivasagam, Ankita Pandey, Jayesh Agiwale, Kriti Hegde, Gaurav Chatterjee, Chetan Dhamne, Maya Prasad, Akanksha Chichra, Shyam Srinivasan, Purvi Mohanty, Hemani Jain, Dhanlaxmi Shetty, Prashant Tembhare, Nikhil Patkar, Gaurav Narula, Papagudi G. Subramanian, Shripad Banavali

Summary: In this study, the long-term toxicities of imatinib treatment in children with pCML were evaluated. The results showed that a significant proportion of patients did not achieve deep molecular response, and some patients had to switch to second-generation TKIs due to poor response. Low bone density and hypovitaminosis D were common long-term toxicities.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Add to Collection

Article Oncology

KIT exon 17 mutations are predictive of inferior outcome in pediatric acute myeloid leukemia with RUNX1::RUNX1T1

Shyam Srinivasan, Chetan Dhamne, Nikhil Patkar, Gaurav Chatterjee, Nirmalya Roy Moulik, Akanksha Chichra, Aneeta Pallath, Prashant Tembhare, Dhanalaxmi Shetty, P. G. Subramanian, Gaurav Narula, Shripad Banavali

Summary: Exon 17 KIT mutations play an important role in predicting relapse in pediatric AML with RUNX1::RUNX1T1 fusion, and a high KIT variant-allele frequency may indicate poor prognosis in these patients. These findings emphasize the need to incorporate KIT mutational analysis into risk stratification for pediatric CBF-AML.

PEDIATRIC BLOOD & CANCER (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.